GB2143542A — Chromogenic quinazolones
Assigned to Novartis AG · Expires 1985-02-13 · 41y expired
What this patent protects
New chromogenic quinazolones are of formula <IMAGE> wherein Y is a polycyclic non-aromatic heterocyclic radical which is attached to the quinazolone moiety through a fused benzene nucleus and is unsubstituted or substituted. and Z is hydrogen, alkyl which is unsubstitute…
USPTO Abstract
New chromogenic quinazolones are of formula <IMAGE> wherein Y is a polycyclic non-aromatic heterocyclic radical which is attached to the quinazolone moiety through a fused benzene nucleus and is unsubstituted or substituted. and Z is hydrogen, alkyl which is unsubstituted or substituted by halogen, hydroxy, cyano or lower alkoxy, or is cycloalkyl, phenyl, benzyl, or phenyl or benzyl which are each substituted by halogen, nitro, cyano, lower alkyl, lower alkoxy or lower alkoxycarbonyl, and the ring A is unsubstituted or substituted by halogen, cyano, nitro, lower alkyl, lower alkoxy or lower alkoxycarbonyl. These compounds are particularly suitable colour formers in pressure-sensitive or heat-sensitive recording materials and produce strong greenish yellow colorations of excellent fastness to light and sublimation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.